drugset
drugset / Trial / NCT01275586

Study of Tasigna®/Nilotinib (AMN107) in Neurofibromatosis (NF1) Patients With Plexiform Neurofibromas

NCT01275586 ↗

Phase 0 Completed 6 enrolled Indiana University Novartis · collab
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this Pilot Study is to determine if NF1 patients with plexiform neurofibromas treated with Tasgina® respond to therapy.

Timeline

Start
2011-01
Primary completion
2016-07
Completion
2016-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Nilotinib Small molecule 400 mg Oral

Indications

neurofibroma neurofibromatosis type 1